EntryPoint Capital’s CONMED CNMD Stock Holding History

EntryPoint Capital’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,679	Closed	-$215K	–	1002
2024 Q1	$215K	Buy	2,679 +1,987	+287%	+$177K	0.19%	94
2023 Q4	$75.8K	Buy	+692	New	+$71.6K	0.07%	525

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

EntryPoint Capital's CNMD Position: Q2 2024 in Review

EntryPoint Capital sold out of CONMED (CNMD) in Q2 2024, closing a stake of 2,679 shares — an estimated $215K sold.

EntryPoint Capital first reported a position in CNMD in Q4 2023 and held it in 2 quarters. The position peaked at $215K in Q1 2024. 290 funds tracked by Wall St. Rank hold CNMD as of Q2 2024.

EntryPoint Capital reported no remaining CONMED position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 2,679 CONMED shares in Q2 2024, an estimated $215K.
EntryPoint Capital first reported a position in CONMED in Q4 2023 and held it in 2 quarters.
EntryPoint Capital's CONMED position peaked at $215K in Q1 2024.
290 funds tracked by Wall St. Rank held CONMED as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.